Skip to main content

Advertisement

SpringerLink
Log in

Predictive value of monocytes and lymphocytes for short-term neutrophil changes in chemotherapy-induced severe neutropenia in solid tumors

  • Original Article
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

Abstract

Purpose

To explore whether monocytes, lymphocytes, and platelets have a predictive value for short-term neutrophil changes in patients with severe neutropenia (SN) induced by chemotherapy.

Methods

Complete blood counts (CBC) were collected from a total of 62 patients with chemotherapy-induced SN from December 2013 to March 2018. CBCs at intervals of 1 day, 2 days, 3 days, 4 days, and 5 days were recorded, and logistic regression analyses were performed to determine whether the monocyte percentage (MP), absolute monocyte count (AMC), lymphocyte percentage (LP), absolute lymphocyte count (ALC), or platelet count (PC) were correlated with short-term neutrophil changes. The areas under the receiver operating characteristic (ROC) curves (AUCs) were calculated for parameters with a P value < 0.05.

Results

The MP was significantly correlated with changes in neutrophils for intervals of 1 to 5 days, while the LP was significantly correlated with changes in neutrophils for intervals of 2 to 5 days. A cutoff value of 6.5% for the MP yielded a sensitivity of 80%, a specificity of 88.6%, and an AUC of 0.908 for predicting an increase in neutrophils on the third day. A cutoff value of 14.75% for the LP yielded a sensitivity of 93.3%, a specificity of 70.3%, and an AUC of 0.812 for predicting an increase in neutrophils on the sixth day.

Conclusions

In chemotherapy-induced neutropenia patients, the MP is the best predictor of short-term neutrophil changes. Close monitoring and proper interpretation of the MP and LP are informative in managing chemotherapy-induced neutropenia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH (2006) Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106(10):2258–2266. https://doi.org/10.1002/cncr.21847

    Article  PubMed  Google Scholar 

  2. Chirivella I, Bermejo B, Insa A, Perez-Fidalgo A, Magro A, Rosello S, Garcia-Garre E, Martin P, Bosch A, Lluch A (2009) Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients. Breast Cancer Res Treat 114(3):479–484. https://doi.org/10.1007/s10549-008-0018-1

    Article  CAS  PubMed  Google Scholar 

  3. Radosavljevic D, Golubicic I, Gavrilovic D, Kezic I, Jelic S (2009) Do the time to chemotherapy response and the dose intensity have an impact on patient outcome in advanced non-small cell lung cancer? J BUON 14(2):203–209

    CAS  PubMed  Google Scholar 

  4. Bosly A, Bron D, Van Hoof A, De Bock R, Berneman Z, Ferrant A, Kaufman L, Dauwe M, Verhoef G (2008) Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP. Ann Hematol 87(4):277–283. https://doi.org/10.1007/s00277-007-0399-y

    Article  CAS  PubMed  Google Scholar 

  5. Jenkins P, Freeman S (2009) Pretreatment haematological laboratory values predict for excessive myelosuppression in patients receiving adjuvant FEC chemotherapy for breast cancer. Annals of oncology : official journal of the European Society for. Med Oncol 20(1):34–40. https://doi.org/10.1093/annonc/mdn560

    Article  CAS  Google Scholar 

  6. Chen K, Zhang X, Deng H, Zhu L, Su F, Jia W, Deng X (2014) Clinical predictive models for chemotherapy-induced febrile neutropenia in breast cancer patients: a validation study. PLoS One 9(6):e96413. https://doi.org/10.1371/journal.pone.0096413

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Oguz A, Karadeniz C, Ckitak EC, Cil V (2006) Which one is a risk factor for chemotherapy-induced febrile neutropenia in childhood solid tumors: early lymphopenia or monocytopenia? Pediatr Hematol Oncol 23(2):143–151. https://doi.org/10.1080/08880010500457673

    Article  PubMed  Google Scholar 

  8. Ray-Coquard I, Borg C, Bachelot T, Sebban C, Philip I, Clapisson G, Le Cesne A, Biron P, Chauvin F, Blay JY, group Es (2003) Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy. Br J Cancer 88(2):181–186. https://doi.org/10.1038/sj.bjc.6600724

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Choi CW, Sung HJ, Park KH, Yoon SY, Kim SJ, Oh SC, Seo JH, Kim BS, Shin SW, Kim YH, Kim JS (2003) Early lymphopenia as a risk factor for chemotherapy-induced febrile neutropenia. Am J Hematol 73(4):263–266. https://doi.org/10.1002/ajh.10363

    Article  CAS  PubMed  Google Scholar 

  10. Shikata H, Yakushijin Y, Yamanouchi J, Azuma T, Yasukawa M (2014) Analysis of chemotherapy-induced neutropenia and optimal timing for prophylactic use of G-CSF in B-cell non-Hodgkin lymphoma patients treated with R-CHOP. Int J Clin Oncol 19(1):178–185. https://doi.org/10.1007/s10147-013-0523-z

    Article  CAS  PubMed  Google Scholar 

  11. Bozcuk H, Yildiz M, Artac M, Kocer M, Kaya C, Ulukal E, Ay S, Kilic MP, Simsek EH, Kilickaya P, Ucar S, Coskun HS, Savas B (2015) A prospectively validated nomogram for predicting the risk of chemotherapy-induced febrile neutropenia: a multicenter study. Support Care Cancer 23(6):1759–1767. https://doi.org/10.1007/s00520-014-2531-6

    Article  CAS  PubMed  Google Scholar 

  12. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J (2016) Cancer statistics in China, 2015. CA Cancer J Clin 66(2):115–132. https://doi.org/10.3322/caac.21338

    Article  Google Scholar 

  13. National Comprehensive Cancer Network (2017) NCCN clinical practice guidelines in oncology (NCCN Guidelines). Myeloid growth factors. Version 1. Available at: www.nccn.org. Accessed 7 July 2017

  14. Dulisse B, Li X, Gayle JA, Barron RL, Ernst FR, Rothman KJ, Legg JC, Kaye JA (2013) A retrospective study of the clinical and economic burden during hospitalizations among cancer patients with febrile neutropenia. J Med Econ 16(6):720–735. https://doi.org/10.3111/13696998.2013.782034

    Article  PubMed  Google Scholar 

  15. Weycker D, Li X, Tzivelekis S, Atwood M, Garcia J, Li Y, Reiner M, Lyman GH (2017) Burden of chemotherapy-induced febrile neutropenia hospitalizations in US clinical practice, by use and patterns of prophylaxis with colony-stimulating factor. Support Care Cancer 25(2):439–447. https://doi.org/10.1007/s00520-016-3421-x

    Article  PubMed  Google Scholar 

  16. Jenkins P, Scaife J, Freeman S (2012) Validation of a predictive model that identifies patients at high risk of developing febrile neutropaenia following chemotherapy for breast cancer. Ann Oncol 23(7):1766–1771. https://doi.org/10.1093/annonc/mdr493

    Article  CAS  PubMed  Google Scholar 

  17. Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, Gallagher J, Herrstedt J, Rapoport B, Rolston K, Talcott J (2000) The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18(16):3038–3051. https://doi.org/10.1200/JCO.2000.18.16.3038

    Article  CAS  PubMed  Google Scholar 

  18. Klastersky J, Paesmans M (2013) The Multinational Association for Supportive Care in Cancer (MASCC) risk index score: 10 years of use for identifying low-risk febrile neutropenic cancer patients. Support Care Cancer 21(5):1487–1495. https://doi.org/10.1007/s00520-013-1758-y

    Article  PubMed  Google Scholar 

  19. de Naurois J, Novitzky-Basso I, Gill MJ, Marti FM, Cullen MH, Roila F, Group EGW (2010) Management of febrile neutropenia: ESMO clinical practice guidelines. Ann Oncol 21(Suppl 5):v252–v256. https://doi.org/10.1093/annonc/mdq196

    Article  PubMed  Google Scholar 

  20. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld R, Pizzo PA, Rolston KV, Shenep JL, Young LS (2002) 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34(6):730–751. https://doi.org/10.1086/339215

    Article  PubMed  Google Scholar 

  21. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR, Infectious Diseases Society of A (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 52(4):e56–e93. https://doi.org/10.1093/cid/cir073

    Article  PubMed  Google Scholar 

  22. Lalami Y, Paesmans M, Muanza F, Barette M, Plehiers B, Dubreucq L, Georgala A, Klastersky J (2006) Can we predict the duration of chemotherapy-induced neutropenia in febrile neutropenic patients, focusing on regimen-specific risk factors? A retrospective analysis. Ann Oncol 17(3):507–514. https://doi.org/10.1093/annonc/mdj092

    Article  CAS  PubMed  Google Scholar 

  23. San Matias S, Clemente M, Giner-Bosch V, Giner V (2011) Predicting the duration of chemotherapy-induced neutropenia: new scores and validation. Ann Oncol 22(1):181–187. https://doi.org/10.1093/annonc/mdq332

    Article  CAS  PubMed  Google Scholar 

  24. Lyman GH, Abella E, Pettengell R (2014) Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: a systematic review. Crit Rev Oncol Hematol 90(3):190–199. https://doi.org/10.1016/j.critrevonc.2013.12.006

    Article  PubMed  Google Scholar 

  25. Carmona-Bayonas A, Jimenez-Fonseca P, Virizuela Echaburu J, Antonio M, Font C, Biosca M, Ramchandani A, Martinez J, Hernando Cubero J, Espinosa J, Martinez de Castro E, Ghanem I, Beato C, Blasco A, Garrido M, Bonilla Y, Mondejar R, Arcusa Lanza MA, Aragon Manrique I, Manzano A, Sevillano E, Castanon E, Cardona M, Gallardo Martin E, Perez Armillas Q, Sanchez Lasheras F, Ayala de la Pena F (2015) Prediction of serious complications in patients with seemingly stable febrile neutropenia: validation of the clinical index of stable febrile neutropenia in a prospective cohort of patients from the FINITE study. J Clin Oncol 33(5):465–471. https://doi.org/10.1200/JCO.2014.57.2347

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Teaching Hospital of Fujian Medical University, Fujian Provincial Cancer Hospital, Fuma Road 420, Fuzhou, Fujian, People’s Republic of China

    Buhong Zheng, Zhiyu Huang, Yunxia Huang, Liang Hong, Jinluan Li & Junxin Wu

Authors
  1. Buhong Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zhiyu Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yunxia Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Liang Hong
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jinluan Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Junxin Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Junxin Wu.

Ethics declarations

Conflict of interest

The authors declare that they have no conflicts of interest.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zheng, B., Huang, Z., Huang, Y. et al. Predictive value of monocytes and lymphocytes for short-term neutrophil changes in chemotherapy-induced severe neutropenia in solid tumors. Support Care Cancer 28, 1289–1294 (2020). https://doi.org/10.1007/s00520-019-04946-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-019-04946-3

Keywords

Search

Navigation